CMI-NENThe SymposiumRon Handels PhD

Ron Handels PhD

Alzheimer Center Limburg, Maastricht University
Assistant professor

Early health-economic evaluation of new technologies in Alzheimer's disease

Novel health technologies are continuously being developed and generally expected to be beneficial. However, during their development the optimal implementation is often unclear and some technologies eventually do not meet their expectations. Evidence is needed on the value of health technologies in their early stage of development, to support stakeholders (industry, regulators, payers, and health-care providers) in decision making linked to their further development and eventual introduction in routine care. This presentation provides a variety of examples of (early) health-technology assessment of (imaging) diagnostics, treatment and care interventions in Alzheimer’s disease.


I work as an assistant professor at the Alzheimer Centre Limburg at Maastricht University and am affiliated to the Karolinska Institutet. I'm part of the International Pharmaco-Economic collaboration on Alzheimer’s Disease ( My background is in epidemiology and cost-effectiveness analysis in Alzheimer’s disease (AD). I perform research in the area of (early) cost-effectiveness of diagnosis and treatment of AD, and natural AD disease progression. My work has been funded by national and international funding schemes (among which ZonMw, H2020, JPND and IMI). On an occasional basis I provide advisory for pharmaceutical organizations.